The BCR-ABL1 Transcript Type Affects Outcomes in Ph+ CML Treated With Front-Line Imatinib
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
American Journal of Hematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
The BCR-ABL1 Transcript Type Influences Response and Outcome in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Patients Treated Frontline With Imatinib
Am. J. Hematol 2017 May 30;[EPub Ahead of Print], F Castagnetti, G Gugliotta, M Breccia, A Iurlo, L Levato, F Albano, P Vigneri, E Abruzzese, G Rossi, S Rupoli, F Cavazzini, B Martino, E Orlandi, P Pregno, M Annunziata, E Usala, M Tiribelli, S Sica, M Bonifacio, C Fava, F Gherlinzoni, M Bocchia, S Soverini, MT Bochicchio, M Cavo, M Giovanni, G Saglio, F Pane, M Baccarani, G RostiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.